e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
Pontali Emanuele, Sotgiu Giovanni, D'Ambrosio Lia, Centis Rosella, Migliori Giovanni Battista
Source:
Eur Respir J 2016; 47: 394-402
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pontali Emanuele, Sotgiu Giovanni, D'Ambrosio Lia, Centis Rosella, Migliori Giovanni Battista. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline
Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017
Year: 2017
Mycobacterium tuberculosis
transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis
Source: Eur Respir J, 50 (4) 1701044; 10.1183/13993003.01044-2017
Year: 2017
Multidrug-resistant tuberculosis in children: evidence from global surveillance
Source: Eur Respir J 2013; 42: 701-707
Year: 2013
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1600803; DOI: 10.1183/13993003.00803-2016
Year: 2017
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence
Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019
Year: 2020
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review
Source: Eur Respir J, 52 (1) 1800934; 10.1183/13993003.00934-2018
Year: 2018
Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Defining optimal fluoroquinolone exposure against
Mycobacterium tuberculosis
: contribution of murine studies
Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020
Year: 2021
Contact investigation for tuberculosis: a systematic review and meta-analysis
Source: Eur Respir J 2013; 41: 140-156
Year: 2013
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017
Year: 2017
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
Is multidrug-resistant TB more common in children? An analysis of surveillance data
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Source: Eur Respir J 2007; 30: 623-626
Year: 2007
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
Source: Eur Respir J 2009; 33: 871-881
Year: 2009
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis
Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016
Year: 2017
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence
Source: Eur Respir J 2013; 42: 288-290
Year: 2013
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis
Source: Eur Respir J 2015; 46: 444-455
Year: 2015
Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis
Source: Eur Respir J 2014; 44: 973-984
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept